These findings indicate that TCR135 can not only directly kill HLA-DP5+EBNA1+ tumor cells, but also recognize EBNA1 presented by APCs and then mediate indirect killing of HLA II–negative tumor cells in a TNF-α–dependent manner. Here, TNF is linked to neoplasm.